Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q8NC60

UPID:
NOA1_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q8NC60; Q8N7L6; Q9BSQ9

BACKGROUND:
The function of Nitric oxide-associated protein 1 is integral to mitochondrial health, influencing both protein synthesis within the mitochondria and the respiratory processes essential for energy production. This protein's involvement in the regulation of cell death and its potential role in organizing the respiratory chain supercomplexes highlight its importance in cellular metabolism and survival. The GTP-binding capability of this protein further emphasizes its regulatory capacity in mitochondrial dynamics.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Nitric oxide-associated protein 1 offers a pathway to novel therapeutic avenues. Given its critical role in mitochondrial operations and apoptosis, targeting this protein could yield breakthroughs in treating conditions linked to mitochondrial impairments or excessive cell death.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.